Recent Analyst Ratings for CervoMed Inc.
Date | Price Target | Rating | Analyst |
---|---|---|---|
12/17/2024 | Buy → Neutral | H.C. Wainwright | |
12/11/2024 | Buy → Neutral | Chardan Capital Markets | |
12/11/2024 | Overweight → Underweight | Morgan Stanley | |
12/10/2024 | Buy → Hold | D. Boral Capital | |
12/6/2024 | $45.00 | Buy | ROTH MKM |
12/5/2024 | $42.00 | Buy | H.C. Wainwright |
9/18/2024 | $55.00 | Buy | Chardan Capital Markets |
7/26/2024 | $35.00 | Overweight | Morgan Stanley |
2/15/2024 | $50.00 | Buy | Canaccord Genuity |
CervoMed Inc. Press Releases
Fastest customizable press release news feed in the world
CervoMed Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia Conference
— Data from the first 16 weeks of the open-label extension phase of the RewinD-LB trial are expected in 1Q 2025 and will include data from participants who have received capsules from a more recently manufactured batch of neflamapimod — — Pharmacokinetic data obtained in a food-effect study in healthy volunteers in 4Q 2024 indicates that the new capsules achieved targeted mean plasma concentrations — — Within-subject comparison of certain participants who received older capsules during the double-blind phase of the RewinD-LB trial and new capsules in the open-label extension phase indicated that participants receiving newer batch capsules, on average, achieved targeted plasma concentration
CervoMed to Present at the 8th International Lewy Body Dementia Conference
BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that topline results from the Phase 2b RewinD-LB study will be presented at the 8th International Lewy Body Dementia Conference (ILBDC), being held in Amsterdam, on January 31, 2025. The initial topline results for the Phase 2b study of neflamapimod in dementia with Lewy bodies (DLB) were previously disclosed on December 10, 2024 and are available here. Details of the ILBDC presentation are as follow: Abstract Title: Efficacy and safety results of the RewinD-LB phase 2b clinical trial of neflamapimod in deme
CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Dec. 12, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO) (the "Company"), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that it has granted equity awards as a material inducement to the employment of two new employees. On December 6, 2024, the Company granted options to purchase an aggregate of 14,753 shares of common stock to two new employees. Each option has an exercise price of $11.91, the closing price of the Company's common stock on the grant date, and each will vest in 36 equal installments on the last day of each month over a three-year period, subject to the employee's continued employment with the Co
CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies
—Neflamapimod did not demonstrate statistically significant effects versus placebo on primary and secondary endpoints at 16 weeks— —Favorable safety and tolerability results with no new safety signal identified— —Target plasma drug concentrations not achieved during 16-week double-blind phase of the trial— —Trial participants continue to receive neflamapimod during open-label extension— BOSTON, Dec. 10, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO) ("CervoMed" or the "Company"), a clinical-stage company focused on developing treatments for age-related neurologic disorders, today announced topline data from the RewinD-LB Phase 2b clinical trial evaluating neflamapimod for the tre
CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia
Designation underscores significant unmet need in frontotemporal dementia and the potential role of neflamapimod in multiple neurologic disorders On track to report topline data from the RewinD-LB Phase 2b clinical trial in early-stage dementia with Lewy bodies (DLB) in December 2024 BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical-stage company focused on developing treatments for age-related neurologic disorders, today announced that its oral investigational drug neflamapimod has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of frontotemporal dementia (FTD). "We are pleased to have received
CervoMed Announces Key Senior Leadership Appointments
BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today reported two senior leadership appointments to advance continued development of neflamapimod. Claudia Ordonez, MD, joined CervoMed as Senior Vice President, Medical Science in October 2024. Dr. Ordonez was previously Chief Medical Officer at two biotech companies and has significant expertise with both early and late-stage drug development. She previously led clinical development programs in cystic fibrosis and multiple sclerosis at Vertex and Biogen, respectively. Additionally, Mark De Rosch, Ph.D., FRAPS, recently jo
CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup
The Prix Galien USA Best Startup category recognizes outstanding innovation by therapeutics-focused life science companies that have not yet received their first product approval The award to CervoMed recognizes the advances made by the company towards developing the first treatment for Dementia with Lewy bodies (DLB) BOSTON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical-stage company focused on developing treatments for age-related neurologic disorders, announced today it was awarded by the Galien Foundation the Prix Galien USA 2024 prize in the Best Startup category. Cervomed was selected as one of two recipients from a total of 43 nominees in the Best Start
CervoMed to Participate in Upcoming Investor Conferences
BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that the Company's Management will participate in the following investor conferences during the month of November: Sidoti Virtual Micro Cap ConferenceFormat: Corporate presentation Date: Thursday, November 14, 2024Time: 2:30 PM ETWebcast Link: click here Stifel 2024 Healthcare ConferenceFormat: Corporate presentation Date: Tuesday, November 19, 2024Time: 3:00 PM ETWebcast Link: click here The webcast of the presentations will be accessible in the Investor section of the CervoMed website https://www.cervomed
CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)
Data from the AscenD-LB Phase 2a trial in DLB confirm recent scientific literature indicating that plasma glial fibrillary acid protein (GFAP) is a robust measure of neurodegenerative disease activity in DLB Neflamapimod treatment previously led to significant reduction in plasma GFAP levels (p=0.015 versus placebo) and these reductions were associated with an improvement in clinical outcomes The RewinD-LB Phase 2b clinical study successfully enrolled a DLB patient population that is optimized to show the treatment effect of neflamapimod when topline data are reported in December BOSTON, Nov. 04, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical-stage company focused on d
CervoMed Announces Last Patient Last Visit in Phase 2b RewinD-LB Trial of Neflamapimod for the Treatment of Early-Stage Dementia with Lewy Bodies (DLB)
• On track to report topline data from the Phase 2b trial in December 2024 • Neflamapimod has the potential to restore function and improve cognitive and motor functions in DLB patients • 96% of patients enrolled in RewinD-LB completed the 16-week portion of the study, of which 98% continued into the open label extension BOSTON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical-stage company focused on developing treatments for age-related neurologic disorders, today announced the Last Patient Last Visit in RewinD-LB, a Phase 2b clinical trial evaluating neflamapimod in patients with early-stage dementia with Lewy bodies (DLB). CervoMed remains on track to report
CervoMed Inc. Analyst Ratings
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
CervoMed downgraded by H.C. Wainwright
H.C. Wainwright downgraded CervoMed from Buy to Neutral
CervoMed downgraded by Chardan Capital Markets
Chardan Capital Markets downgraded CervoMed from Buy to Neutral
CervoMed downgraded by Morgan Stanley
Morgan Stanley downgraded CervoMed from Overweight to Underweight
CervoMed downgraded by D. Boral Capital
D. Boral Capital downgraded CervoMed from Buy to Hold
ROTH MKM initiated coverage on CervoMed with a new price target
ROTH MKM initiated coverage of CervoMed with a rating of Buy and set a new price target of $45.00
H.C. Wainwright initiated coverage on CervoMed with a new price target
H.C. Wainwright initiated coverage of CervoMed with a rating of Buy and set a new price target of $42.00
Chardan Capital Markets initiated coverage on CervoMed with a new price target
Chardan Capital Markets initiated coverage of CervoMed with a rating of Buy and set a new price target of $55.00
Morgan Stanley initiated coverage on CervoMed with a new price target
Morgan Stanley initiated coverage of CervoMed with a rating of Overweight and set a new price target of $35.00
Canaccord Genuity initiated coverage on CervoMed with a new price target
Canaccord Genuity initiated coverage of CervoMed with a rating of Buy and set a new price target of $50.00
CervoMed Inc. Insider Purchases
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
CFO & GC Elder William Robert bought $18,160 worth of shares (1,000 units at $18.16), increasing direct ownership by 375% to 1,267 units (SEC Form 4)
4 - CervoMed Inc. (0001053691) (Issuer)
CervoMed Inc. Insider Trading
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
SEC Form 4 filed by Director Gregoire Sylvie
4 - CervoMed Inc. (0001053691) (Issuer)
SEC Form 4 filed by CFO & GC Elder William Robert
4 - CervoMed Inc. (0001053691) (Issuer)
SEC Form 4 filed by Chief Operating Officer Cobuzzi Robert Joseph Jr.
4 - CervoMed Inc. (0001053691) (Issuer)
SEC Form 4 filed by SVP, Clinical Development Blackburn Kelly
4 - CervoMed Inc. (0001053691) (Issuer)
SEC Form 4 filed by CEO & President Alam John J
4 - CervoMed Inc. (0001053691) (Issuer)
CFO & GC Elder William Robert bought $18,160 worth of shares (1,000 units at $18.16), increasing direct ownership by 375% to 1,267 units (SEC Form 4)
4 - CervoMed Inc. (0001053691) (Issuer)
SEC Form 4 filed by CEO & President Alam John J
4 - CervoMed Inc. (0001053691) (Issuer)
SEC Form 4 filed by Director Boger Joshua S
4 - CervoMed Inc. (0001053691) (Issuer)
SEC Form 4 filed by Director Gregoire Sylvie
4 - CervoMed Inc. (0001053691) (Issuer)
SEC Form 4 filed by Director Hollingsworth Jane H
4 - CervoMed Inc. (0001053691) (Issuer)
CervoMed Inc. SEC Filings
CervoMed Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
8-K - CervoMed Inc. (0001053691) (Filer)
CervoMed Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
8-K - CervoMed Inc. (0001053691) (Filer)
CervoMed Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
8-K - CervoMed Inc. (0001053691) (Filer)
CervoMed Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
8-K - CervoMed Inc. (0001053691) (Filer)
CervoMed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
8-K - CervoMed Inc. (0001053691) (Filer)
SEC Form 10-Q filed by CervoMed Inc.
10-Q - CervoMed Inc. (0001053691) (Filer)
CervoMed Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
8-K - CervoMed Inc. (0001053691) (Filer)
CervoMed Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
8-K - CervoMed Inc. (0001053691) (Filer)
CervoMed Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
8-K - CervoMed Inc. (0001053691) (Filer)
SEC Form 424B3 filed by CervoMed Inc.
424B3 - CervoMed Inc. (0001053691) (Filer)
CervoMed Inc. Leadership Updates
Live Leadership Updates
CervoMed to Appoint William Elder as Chief Financial Officer
BOSTON, May 20, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced the appointment of William (Bill) Elder as Chief Financial Officer, effective June 1, 2024. Mr. Elder will continue to serve as General Counsel and Corporate Secretary. He will succeed William Tanner who has served as Chief Financial Officer to CervoMed and its predecessor, EIP Pharma, since September 2022. Mr. Tanner will continue as a consultant to CervoMed following the transition. "Bill's deep biopharmaceutical and financial expertise and strong track record of enhancing operational capabilities makes him
CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
- Announced private placement of up to $149.4 million led by RA Capital Management with participation from Armistice Capital, Special Situations Funds and Soleus Capital; pro forma cash and cash equivalents from upfront proceeds expected to provide runway through the end of 2025 - CervoMed on track to complete enrollment in 2Q 2024 in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia with Lewy bodies (DLB); topline data expected in 4Q 2024 - Integrated summary of results from AscenD-LB Phase 2a trial published in peer-reviewed journal and presentations at a major scientific conference further inform on the potential of neflamapimod in DLB and proba
CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board
Dr. Boger is the founder, and retired CEO and Board Chair, of Vertex Pharmaceuticals CervoMed on track to complete enrollment in 1H 2024 in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia with Lewy bodies; topline data expected in 2H 2024 BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical-stage company developing treatments for degenerative diseases of the brain, today announced the appointment of Joshua Boger, Ph.D., to its Board of Directors (Board) and as Chair of the Board. Dr. Boger is an innovative scientist and highly successful business executive who brings extensive drug development and biopharmaceutical comp
CervoMed Inc. Large Ownership Changes
This live feed shows all institutional transactions in real time.
SEC Form SC 13G filed by CervoMed Inc.
SC 13G - CervoMed Inc. (0001053691) (Subject)
SEC Form SC 13G filed by CervoMed Inc.
SC 13G - CervoMed Inc. (0001053691) (Subject)
SEC Form SC 13G/A filed by CervoMed Inc. (Amendment)
SC 13G/A - CervoMed Inc. (0001053691) (Subject)
SEC Form SC 13D/A filed by CervoMed Inc. (Amendment)
SC 13D/A - CervoMed Inc. (0001053691) (Subject)